266 related articles for article (PubMed ID: 26204844)
1. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
[TBL] [Abstract][Full Text] [Related]
2. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate.
Catalano A; Morabito N; Di Stefano A; Morini E; Basile G; Faraci B; Loddo S; Ientile R; Lasco A
J Endocrinol Invest; 2015 Aug; 38(8):859-63. PubMed ID: 25952299
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
5. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
Middleton ET; Steel SA; Aye M; Doherty SM
J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
[TBL] [Abstract][Full Text] [Related]
6. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
7. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Bruyère O; Collette J; Rizzoli R; Decock C; Ortolani S; Cormier C; Detilleux J; Reginster JY
Osteoporos Int; 2010 Jun; 21(6):1031-6. PubMed ID: 19813043
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.
Abboskhujaeva LS; Ismailov SI; Alikhanova NM
Drugs R D; 2014 Dec; 14(4):315-24. PubMed ID: 25480348
[TBL] [Abstract][Full Text] [Related]
9. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
[TBL] [Abstract][Full Text] [Related]
10. Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
Forni GL; Perrotta S; Giusti A; Quarta G; Pitrolo L; Cappellini MD; D'Ascola DG; Borgna Pignatti C; Rigano P; Filosa A; Iolascon G; Nobili B; Baldini M; Rosa A; Pinto V; Palummeri E
Br J Haematol; 2012 Jul; 158(2):274-282. PubMed ID: 22571408
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
[TBL] [Abstract][Full Text] [Related]
12. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
13. Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Muschitz C; Kocijan R; Pahr D; Patsch JM; Amrein K; Misof BM; Kaider A; Resch H; Pietschmann P
Calcif Tissue Int; 2015 Jun; 96(6):477-89. PubMed ID: 25911186
[TBL] [Abstract][Full Text] [Related]
14. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
15. Effect of strontium ranelate on serum leptin and bone turnover markers in women with established postmenopausal osteoporosis.
Bayhan I; Dogan NU; Ozaksit G; Uygur D; Ugurlu N; Ugur M
J Reprod Med; 2013; 58(7-8):319-23. PubMed ID: 23947082
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Recker RR; Marin F; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Farrerons J; Sanz B; Oertel H; Stepan J
J Bone Miner Res; 2009 Aug; 24(8):1358-68. PubMed ID: 19338452
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
20. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
Roschger P; Manjubala I; Zoeger N; Meirer F; Simon R; Li C; Fratzl-Zelman N; Misof BM; Paschalis EP; Streli C; Fratzl P; Klaushofer K
J Bone Miner Res; 2010 Apr; 25(4):891-900. PubMed ID: 20437609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
